High-Quality Probiotic Products

Similac® Probiotic Tri-Blend Safety & Quality

EXCEEDS INDUSTRY STANDARDS1

HIGH-QUALITY PROBIOTIC STRAINS

Abbott has partnered with global bioscience company Chr. Hansen to manufacture Similac Probiotic Tri-Blend.

 

CONTROLLED, RIGOROUS TESTING

Our multiphase production process maintains a high level of safety, often exceeding the microbial testing standards for dietary supplements and infant formula. 

 

PRODUCT POTENCY & STABILITY ENSURED

Tested to confirm strain identity and confirm that the product contains 100% of the quantity of probiotics declared on the label, with shelf stability at room temperature.

 

HIGH-QUALITY PROBIOTIC STRAINS FROM BRANDS YOU TRUST

OVER 200 YEARS OF COMBINED EXPERIENCE

Abbott has partnered with the global bioscience company Chr. Hansen to manufacture Similac Probiotic Tri-Blend. Combined, our companies bring more than 200 years of industry experience. Chr. Hansen, the world’s largest culture manufacturer, develops probiotic strains backed by scientific data, produced within facilities that are compliant with US manufacturing regulations.

 

DNA FINGERPRINTING ENSURES IDENTITY & PURITY

As each new batch of a probiotic strain is produced, DNA fingerprinting is done to confirm that the profiles of the reference culture and the new batch remain identical to ensure we deliver only the original, high-quality strains.

 

CONTAMINANT TESTING THAT GOES BEYOND INDUSTRY STANDARDS

Our rigorous, multiphase microbial contamination testing goes beyond what’s required for both dietary supplements and infant formulas to provide a safe product for hospital use.

SIMILAC PROBIOTIC TRI-BLEND CONTAMINANT TESTING:
Testing required for dietary supplements in the US Testing required for infant formulas in the US Contaminant testing that goes beyond dietary supplement and infant formula requirements in the US
  • E coli
  • Total aerobic microbial count
  • Total yeast and mold
  • Cronobacter spp.
  • Salmonella

 

 
  • Bacillus cereus
  • S aureus
  • Sulphite reducing clostridia
  • Cronobacter spp.*
  • Salmonella*
  • Enterobacteriaceae
  • Listeria monocytogenes
If any contaminants present at any stage, the whole batch is discarded.

 

 

CONTROLLED, RIGOROUS TESTING FOR PURITY & SAFETY

MULTIPLE TESTING POINTS THROUGHOUT PRODUCTION 

Our production process maintains a high level of microbial safety. This helps ensure product safety for all infants.

A UNIQUE MULTISTRAIN, MULTISPECIES BLEND

Excellent product quality supports health of the developing GI tract, promotes a healthy gut microbiome, and is suitable for hospital use2,3 Our unique blend provides multistrain and multispecies probiotics that may have functional advantages over single strains.4

Bifi dobacterium lactis (BB-12®), Bifi dobacterium infantis (BB-02), & Streptococcus thermophilus (TH-4®)

POTENCY & STABILITY ENSURED

FROM DEVELOPMENT TO DELIVERY

REFRIGERATION IS NOT REQUIRED IF STORED AT OR BELOW 25°C (77°F).

STABILITY TESTING

We replicate conditions representative of the finished product in the final packaging to ensure it's shelf stable.

GLOBAL COMPLIANCE

All packaging, from packet to shipping container, is globally compliant with food contact and restricted substance regulations.

PACKAGE INTEGRITY ASSESSMENT

Testing ensures the single-dose packaging provides adequate protection against the introduction of harmful contaminants from packaging through transit, which goes beyond standard practice.

COLD-CHAIN TRANSPORT

Our proven packaging system maintains the integrity of our probiotics, which is crucial during climate fluctuations in shipment.

SIMILAC PROBIOTIC TRI-BLEND DELIVERS A HIGH-QUALITY PROBIOTIC FOR HOSPITAL USE1:

  • Strains with no transferable antibiotic-resistant genes
  • Correct strain and lack of contamination ensured
  • Confirmed viability through stability testing 

CHOOSE THE PROBIOTIC DEVELOPED WITH INFANT SAFETY TOP OF MIND

* Tested in larger batch samples than industry standards require.

References: 1. Data on file. Abbott Nutrition. 2020. 2. Saavedra JM. Nutr Clin Pract. 2007;22(3):351-365. 3. Hemarajata P, et al. Therap Adv Gastroenterol. 2013;6(1):39-51. 4. Timmerman HM, et al. Int J Food Microbiol. 2004;96(3):219-233.